Founded Year

2014

Stage

IPO | IPO

Total Raised

$32.19M

Date of IPO

3/25/2021

Market Cap

87.27B

About VUNO

VUNO (KOSDAQ:338220) delivers standalone, cloud-based, and integrated deep learning applications that improve the workflow of physicians while enhancing patient care. From imaging modalities like X-rays and CT scans to biosignal monitoring systems, VUNO provides a diverse array of services that quantifies and analyzes data to diagnose diseases. The medical diagnostic support platform, VUNO Med, is built on top of a proprietary AI engine, VUNO Net, that leverages high quality large-scale medical data and enables real-time experience and allows the results of services to be analyzed from anywhere.

VUNO Headquarters Location

507, Gangnam-daero, Seocho-gu 6F

Seoul, 06536,

South Korea

+82 (0)2 515 6646

VUNO's Product Videos

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

VUNO's Products & Differentiation

See VUNO's products and how their products differentiate from alternatives and competitors

  • VUNO Med®-BoneAge™

    Deep-learning based Automatic BoneAge Assessment. BoneAge is an innovative and cutting-edge software that was approved as Korea’s first AI-based diagnostic software for bone age assessment. Based on hand X-ray images, it provides an accurate bone age assessment by suggesting 3 nearest matching bone age results within 5 seconds.

    Differentiation

    Increases the consistency and accuracy of bone age assessments and boosts physician confidence in decision making; Enhances the quality of patient care with comprehensive BoneAge Report; Can be used… 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing VUNO

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

VUNO is included in 7 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

M

Medical Devices

8,452 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

H

Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Digital Hospital

98 items

Startups recreating how healthcare is delivered

D

Digital Health

13,084 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

VUNO Patents

VUNO has filed 32 patents.

The 3 most popular patent topics include:

  • Artificial neural networks
  • Medical imaging
  • Artificial intelligence
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/4/2018

6/14/2022

Software architecture, Learning methods, Machine learning, Educational psychology, Psychometrics

Grant

Application Date

1/4/2018

Grant Date

6/14/2022

Title

Related Topics

Software architecture, Learning methods, Machine learning, Educational psychology, Psychometrics

Status

Grant

Latest VUNO News

South Korea clears VUNO's personal ECG device

Aug 4, 2022

The clearance signals the company's move to offer medical AI devices to consumers. Credit: VUNO Medical AI company VUNO has received the South Korean Ministry of Food and Drug Safety's clearance for its personal ECG device. Called Hativ Pro, the portable medical device simply measures a user's heart rate and sends this data through a connected mobile phone app. WHY IT MATTERS VUNO has been offering a range of medical AI solutions for doctors and health facilities. Following this latest government certification, VUNO can finally move towards offering AI medical devices to consumers. With the MFDS clearance, the company plans to soon launch its integrated health management brand Hativ, featuring AI-powered home medical devices that support consumers' daily health management and early diagnosis of chronic diseases. VUNO continues to strengthen its medical AI business based on ECG data, which the company claims have "high potential as a biomarker for various cardiovascular diseases". In South Korea, CVDs are the second leading cause of death after cancer with cases rising each year due to an ageing population. "Through our ECG data-based medical AI project, we will do our best to reduce mortality from cardiovascular disease and contribute to preventive treatment – the future direction of medical care," said VUNO CEO Lee Ye Ha. In the future, VUNO plans to release more home AI medical devices for detecting major heart diseases. THE LARGER TREND In recent months, VUNO has been collecting several regulatory approvals to market its AI medical solutions in South Korea and the rest of Asia-Pacific. In March, VUNO secured the South Korean government's approval for VUNO Med LungQuant, an AI-based lung CT quantification solution for the precise evaluation and screening of lung diseases. Last year, it also received an MFDS clearance for VUNO Med DeepCARS , a medical device that uses AI to analyse a person's risk for cardiac arrest. In the first half of the year, the company also obtained market approvals in Thailand, Saudi Arabia, and Malaysia for its other VUNO Med offerings. Tags:

VUNO Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

VUNO Rank

  • When was VUNO founded?

    VUNO was founded in 2014.

  • Where is VUNO's headquarters?

    VUNO's headquarters is located at 507, Gangnam-daero, Seocho-gu, Seoul.

  • What is VUNO's latest funding round?

    VUNO's latest funding round is IPO.

  • How much did VUNO raise?

    VUNO raised a total of $32.19M.

  • Who are the investors of VUNO?

    Investors of VUNO include Dongwha Pharm, Dongkoo Bio&Pharma, Korea Development Bank, FuturePlay, HB Investment and 10 more.

  • Who are VUNO's competitors?

    Competitors of VUNO include Lunit, Digital Diagnostics, VIDA Diagnostics, Qure.ai, PMX and 15 more.

  • What products does VUNO offer?

    VUNO's products include VUNO Med®-BoneAge™ and 4 more.

You May Also Like

A
Aidoc Medical

Aidoc finds and flags critical findings in medical images. By automatically prioritizing urgent, life-threatening conditions like intracranial hemorrhage and pulmonary embolism, Aidoc saves lives, improves patient care and cuts waiting time for the must urgent patients down to only a few minutes. The always-on AI integrates into a radiologist's workflow, reprioritizing cases without forcing radiologists to change the way they work. Aidoc was founded in 2016 and is based in Tel Aviv, Israel.

Qure.ai Logo
Qure.ai

Qure.ai has developed an artificial intelligence-based system to identify abnormalities in head CT scans. The company aims to leverage deep learning effectively to diagnose diseases from radiology and pathology imaging and create personalized cancer treatment plans from psychopathology imaging and genome sequences. It was founded in 2016 and is based in Mumbai, India.

Ultromics Logo
Ultromics

Ultromics is a global health technology company that provides autonomous echocardiography analysis through AI solutions – empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. Its cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

Viz.ai Logo
Viz.ai

Viz.ai aims to use artificial intelligence and deep learning to automatically identify suspected LVOs (large vessel occlusion) on CTA imaging with the aim of alerting a patient's physician within minutes. The company was founded in 2016 and is based in San Francisco, California.

Enlitic Logo
Enlitic

Enlitic develops a diagnosis system that uses deep learning to analyze medical data in order to enable quick and more accurate detection of diseases that can be identified through medical images such as X-rays and CT scans.

Koios Medical Logo
Koios Medical

Koios Medical is a provider of software solutions for radiologists diagnosing cancer. Using AI algorithms trained on thousands of images combined with data from pathology results, Koios DS™ is decision support for healthcare diagnostics. Koios Medical was formerly known as Clearview Diagnostics. The company was founded in 2012 and is based in Chicago, Illinois.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.